Stock BNTX BIONTECH SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioNTech SE Wiener Boerse

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

End-of-day quote Wiener Boerse
Other stock markets
 06:00:00 2024-06-16 pm EDT 		5-day change 1st Jan Change
82.7 EUR -5.27% Intraday chart for BioNTech SE -5.27% -13.39%
Jun. 18 US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial MT
Jun. 17 Sector Update: Health Care Stocks Ease in Afternoon Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,837 16,071 54,764 34,112 22,730 19,118 - -
Enterprise Value (EV) 1 6,318 14,964 53,372 20,449 11,286 6,444 7,098 7,246
P/E ratio -35.6 x 1,112 x 5.72 x 3.72 x 25 x -43.8 x -34.7 x -34.5 x
Yield - - - - - - - -
Capitalization / Revenue 63 x 33.3 x 2.89 x 1.97 x 5.95 x 6.96 x 6.98 x 6.87 x
EV / Revenue 58.2 x 31 x 2.81 x 1.18 x 2.96 x 2.35 x 2.59 x 2.6 x
EV / EBITDA -42.8 x -343 x 3.47 x 1.6 x 12.9 x -7.65 x -7.32 x -7.51 x
EV / FCF -26.6 x -188 x 72.5 x 1.55 x 2.42 x -183 x -9.28 x -9.56 x
FCF Yield -3.75% -0.53% 1.38% 64.6% 41.3% -0.55% -10.8% -10.5%
Price to Book 13.9 x 11.8 x 4.62 x 1.7 x 1.12 x 0.96 x 1 x 1.02 x
Nbr of stocks (in thousands) 226,262 240,786 241,521 243,019 237,716 241,319 - -
Reference price 2 30.22 66.74 226.7 140.4 95.62 79.22 79.22 79.22
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 108.6 482.3 18,977 17,311 3,819 2,745 2,740 2,782
EBITDA 1 -147.6 -43.67 15,359 12,766 873.8 -842.3 -969.8 -965.2
EBIT 1 -181.5 -82.42 15,284 12,643 690.4 -989.2 -1,063 -1,038
Operating Margin -167.16% -17.09% 80.54% 73.03% 18.08% -36.04% -38.81% -37.29%
Earnings before Tax (EBT) 1 -179.4 -145.8 15,046 12,954 1,186 -370.1 -533.1 -530.6
Net income 1 -179.1 15.2 10,292 9,434 930.3 -419.2 -548.1 -556.9
Net margin -164.89% 3.15% 54.24% 54.5% 24.36% -15.27% -20.01% -20.02%
EPS 2 -0.8500 0.0600 39.63 37.77 3.830 -1.810 -2.285 -2.293
Free Cash Flow 1 -237.1 -79.51 735.7 13,214 4,667 -35.22 -764.6 -757.7
FCF margin -218.37% -16.48% 3.88% 76.34% 122.19% -1.28% -27.91% -27.23%
FCF Conversion (EBITDA) - - 4.79% 103.51% 534.06% - - -
FCF Conversion (Net income) - - 7.15% 140.06% 501.62% - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 5,532 6,375 3,196 3,461 4,278 1,277 167.7 895.3 1,479 187.6 144.9 539.8 1,918 208 181.8
EBITDA 1 4,726 - - 2,421 3,322 685.8 - 114.4 605 -468.9 -711 -231 866 - -
EBIT 1 4,700 4,753 2,210 2,388 3,293 654.4 -563.3 73.1 526.2 -507.2 -661.9 -377.1 584.3 -709.2 -729.7
Operating Margin 84.95% 74.56% 69.13% 68.98% 76.97% 51.25% -335.9% 8.16% 35.58% -270.36% -456.83% -69.85% 30.46% -341% -401.48%
Earnings before Tax (EBT) 1 4,714 5,018 2,319 2,444 3,173 707.7 -412.2 227.4 663.2 -331.8 -510.8 -225.7 771.7 -522.6 -527.7
Net income 1 3,166 3,699 1,672 1,785 2,279 502.2 -190.4 160.6 457.9 -315.1 -456.7 -258 690.6 -522.6 -527.7
Net margin 57.23% 58.02% 52.31% 51.57% 53.26% 39.33% -113.54% 17.94% 30.96% -167.96% -315.21% -47.79% 36% -251.26% -290.36%
EPS 2 12.18 14.24 6.450 6.980 9.260 2.050 -0.7900 0.6700 1.900 -1.310 -2.083 -1.472 3.008 -1.796 -2.039
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 3/30/22 5/9/22 8/8/22 11/7/22 3/27/23 5/8/23 8/7/23 11/6/23 3/20/24 5/6/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 519 1,107 1,391 13,663 11,445 12,674 12,020 11,872
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -237 -79.5 736 13,214 4,667 -35.2 -765 -758
ROE (net income / shareholders' equity) -47.1% 1.63% 155% 59.1% 4.62% -2.75% -3.04% -3.49%
ROA (Net income/ Total Assets) -24.7% 0.98% 113% 48.2% 4.02% -1.99% -2.17% -3.49%
Assets 1 725.3 1,558 9,075 19,555 23,143 21,113 25,246 15,949
Book Value Per Share 2 2.180 5.680 49.00 82.50 85.20 82.70 79.60 77.70
Cash Flow per Share 2 -0.9400 -0.0500 3.430 55.80 22.60 3.040 -0.5000 -0.7800
Capex 1 38.6 66 128 329 249 436 363 339
Capex / Sales 35.54% 13.69% 0.67% 1.9% 6.53% 15.88% 13.27% 12.18%
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
79.22 EUR
Average target price
103.5 EUR
Spread / Average Target
+30.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
ARGENX SE Stock argenx SE
+8.24% 23.61B
GENMAB A/S Stock Genmab A/S
-16.19% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
INSMED INCORPORATED Stock Insmed Incorporated
+119.39% 10.96B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. BNTX Stock
  5. Financials BioNTech SE